DNBSEQ[™] Service Overview Small RNA Sequencing



Service Description

Small RNAs are a type of non-coding RNA (ncRNA) molecule that are less than 200nt in length. They are often involved in gene silencing and post-transcriptional regulation of gene expression. Small RNA sequencing is used to discover novel small RNAs, examine the differential expression of all small RNAs and to characterize variations with single-base resolution.

Unique Molecular Identifier (UMI) Service Option

Unique Molecular Identifiers (UMIs) can be utilized to eliminate undesirable PCR duplicates derived from a single molecule. After PCR, molecules sharing a UMI are assumed to be derived from the same input molecule. As such, UMI counts offer superior results to counting reads, leading to more accurate estimates of quantitative small RNA expression[1]. UMI technology is especially beneficial to customers doing research on rare and precious samples or samples containing less RNAs, such as exosomes.

Our DNBSEQ™ Small RNA sequencing service with optional UMI technology delivers accurate, affordable and high-quality sequencing data to support your academic and clinical research applications.

Sequencing Service Specification

DNBSEQ[™] Small RNA Sequencing Services are performed with the DNBSEQ[™] technology, featuring cPAS and DNA Nanoballs (DNB[™]) technology for superior data quality[2].

A

Sample preparation and services

- 50bp single-end sequencing reads
- · Standard output 20 Million reads per sample
- UMI technology to enhance the quantification accuracy
- Sequencing data and bioinformatics analysis are available in standard file formats
- Advanced RNA data visualization and data mining with Dr.Tom system



Sequencing Quality Standard

Guaranteed ≥80% of bases with quality score of ≥Q30

Turnaround Time




- Typical 27 working days from sample QC acceptance to filtered data availability
- · Expedited services are available



Project workflow


We care for your samples from the start through to the result reporting. Highly experienced laboratory professionals follow strict quality procedures to ensure the integrity of your





DNBSEQ™ Sequencing Technology

DNBSEQTM is an innovative high-throughput sequencing solution, developed by BGI's Complete Genomics subsidiary in Silicon Valley. The system is powered by combinatorial Probe-Anchor Synthesis (cPAS), linear isothermal Rolling-Circle Replication and DNA Nanoballs (DNBTM) technology, followed by high-resolution digital imaging.



The combination of linear amplification and DNB™ technology reduces the error rate while enhancing the signal. The size of the DNB is controlled in such a way that only one DNB is bound per active site on the DNBSEQ™ flow cell. This densely patterned array technology provides optimal sequencing accuracy and increases flow cell utilization.

Data Analysis

In addition to data output, BGI offers a range of standard and customized bioinformatics pipelines for your small RNA sequencing project.

Reports and output data files are delivered in industry standard FASTQ, and Excel file formats with publication-ready tables and figures.

STANDARD BIOINFORMATICS ANALYSIS

- · Data filtering
- · Length distribution of small RNAs
- · Analysis of common and specific sequences between two samples
- Small RNAs distribution across selected genome
- Identification of rRNAs, tRNAs, snRNAs, snoRNAs, etc.
- · Identification of repeat associated small RNAs
- · Identification of small RNA sequences which could align to exon/intron
- · Identification of known miRNAs by aligning to designated part of miRBase
- · Analysis of the expression pattern of known miRNAs
- · Classification of small RNAs into several categories based on customer preference
- · Prediction of novel miRNAs and their secondary structures by Mireap and miRDeep from unannotated small RNAs
- Family analysis of known miRNAs

Dr. Tom SYSTEM ANALYSIS

- · miRNA target gene analysis
- · GO and Pathway annotation for target genes
- miRNA-mRNA interaction, IncRNA-mRNA interaction analysis
- Co-expression Interaction Network Analysis

Sample Requirements

We can process your sample of human, plant, or animal samples with the following general requirements:

	RNA Amount and Concentration	Minimum Sample Volume	Quantitative Result
Regular sample	mass ≥1μg Concentration ≥50ng/μl	15 µl	RIN≥6.5 (plant) RIN ≥8.0 (human/animal)
FFPE RNA	mass ≥1μg Concentration ≥50ng/μl	15 µl	RIN ≥2.0 DV ₂₀₀ ≥30%
Small RNA of Plasma/serum/exosome	mass ≥20ng Concentration ≥1ng/µl	10μΙ	N/A

Stable and High-Quality Data Performance

Technical reproducibility[3]

To demonstrate the high technical reproducibility of the DNBSEQTM technology platform, six human brain samples, two heart samples and two blood samples were sequenced. Reproducibility was assessed by using six technical replicates of human brain sample (see Fig. 1). The median correlation between the six replicates was 0.98, and the 25% and 75% quantile were 0.98 and 0.99, respectively.




Fig. 1 Correlation matrix of brain (six technical replicates), heart (two technical replicates), and blood (two biological replicates) samples, sequenced by the DNBSEQ system.

References

- [1] Fu Y, Wu PH, Beane T, Zamore PD, Weng Z: Elimination of PCR duplicates in RNA-seq and small RNA-seq using unique molecular identifiers. BMC Genomics 2018;19:531.
- [2] Drmanac R, Sparks AB, Callow MJ, Halpern AL, Burns NL, Kermani BG, Carnevali P, Nazarenko I, Nilsen GB, Yeung G, Dahl F, Fernandez A, Staker B, Pant KP, Baccash J, Borcherding AP, Brownley A, Cedeno R, Chen L, Chernikoff D, Cheung A, Chirita R, Curson B, Ebert JC, Hacker CR, Hartlage R, Hauser B, Huang S, Jiang Y, Karpinchyk V, Koenig M, Kong C, Landers T, Le C, Liu J, McBride CE, Morenzoni M, Morey RE, Mutch K, Perazich H, Perry K, Peters BA, Peterson J, Pethiyagoda CL, Pothuraju K, Richter C, Rosenbaum AM, Roy S, Shafto J, Sharanhovich U, Shannon KW, Sheppy CG, Sun M, Thakuria JV, Tran A, Vu D, Zaranek AW, Wu X, Drmanac S, Oliphant AR, Banyai WC, Martin B, Ballinger DG, Church GM, Reid CA: Human genome sequencing using unchained base reads on self-assembling DNA nanoarrays. Science 2010;327:78-81.
- [3] Fehlmann T, Reinheimer S, Geng C, Su X, Drmanac S, Alexeev A, Zhang C, Backes C, Ludwig N, Hart M, An D, Zhu Z, Xu C, Chen A, Ni M, Liu J, Li Y, Poulter M, Li Y, Stahler C, Drmanac R, Xu X, Meese E, Keller A: cPAS-based sequencing on the BGISEQ-500 to explore small non-coding RNAs. Clin Epigenetics 2016;8:123.

Request for Information or Quotation

Contact your BGI account representative for the most affordable rates in the industry and to discuss how we can meet your specific project requirements or for expert advice on experiment design, from sample to bioinformatics.

info@bgi.com www.bgi.com

BGI Offices BGI Americas

BGI Americas	BGI Europe
One Broadway, 3rd Floor	Ole Maaløes '
Cambridge, MA 02142,	DK-2200 Cop
USA	Denmark

e Maaløes Vej 3, (-2200 Copenhagen N. Denmark

BGI Asia

Building NO.7, BGI Park, No.21 Hongan 3rd Street, Yantian District, Shenzhen

BGI Australia

L6, CBCRC, 300 Herston Road, Herston, Brisbane, Queensland 4006, Australia

For Research Use Only. Not for use in diagnostic procedures (except as specifically noted).

Copyright© BGI 2022. All trademarks are the property of BGI, or their respective owners. This material contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such informa-tion which may not comply with any legal process, regulation, registration or usage in the country of your origin. Note, BGI's genetic testing products have not been cleared or approved by the US FDA and are not available in the USA. For Research Use Only. Unless otherwise informed, all sequencers and sequencing reagents are not available in Germany, USA, Spain, UK, Hong Kong, Sweden, Belgium or Italy. Certain sequencing services are not available in USA and Hong Kong. Please contact a representative for regional availability. The company reserves the right of final interpretation.







We Sequence, You Discover